Canaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65

Benzinga Newsdesk www.benzinga.com Positive 58.8%

Neg 0% Neu 0% Pos 58.8%

Canaccord Genuity analyst Sumant Kulkarni initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $65.